The development of an effective synthetic route of rilpivirine

BACKGROUND: Rilpivirine (RPV) was approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Significantly, rilpivirine is three fold more potent than etravirine. Once-daily, it is used with a low oral dose (25 mg/tablet...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Chem
Päätekijät: Zhang, Tao, Yang, Jiapei, Zhou, Zhongxia, Fu, Zhipeng, Cherukupalli, Srinivasulu, Kang, Dongwei, Zhan, Peng, Liu, Xinyong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2021
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8017658/
https://ncbi.nlm.nih.gov/pubmed/33810807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13065-021-00749-y
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia